Skip to main content
Premium Trial:

Request an Annual Quote

Collin D Silva Resigns as CEO of Transgenomic; Remains Board Chairman

NEW YORK, April 4 (GenomeWeb News) - Collin D'Silva has resigned as chief executive officer of Transgenomic, the company said yesterday.

 

Michael Summers, the company's chief financial officer, has taken over as interim CEO until a new chief executive has been found. He also remains CFO.

 

D'Silva will remain chairman of the board of directors. He will manage strategic customer relationships and evaluate corporate strategic alternatives.

 

A company spokesperson did not cite a reason why D'Silva stepped down as CEO.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.